Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action

Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata

RINEHART, K. L. J., Holt, T. G., Fregeau, N. L., Stroh, J. G., Keifer, P. A., Sun, F.-R., Li, L. H., & Martin, D. G. (1990) · The Journal of Organic Chemistry · doi:10.1021/jo00302a007 · Cited by 493 · see citing works

DNA Sequence- and Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, a Potent Antitumor Compound from the Caribbean Tunicate Ecteinascidia turbinata

Pommier, Y. G., Kohlhagen, G., Bailly, C., Waring, M. J., Mazumder, A., & Kohn, K. W. (1996) · Biochemistry · doi:10.1021/bi960306b · Cited by 304 · see citing works

Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line

Drummond, J. T., Anthoney, A., Brown, R. E., & Modrich, P. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19645 · Cited by 295 · see citing works

In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.

Fink, D. A., Zheng, H., Nebel, S., Norris, P. S., Aebi, S. P., Lin, T., Nehmé, A., Christen, R. D., Haas, M., MacLeod, C. L., et al. (1997) · PubMed · Cited by 277 · see citing works

Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA toward the Major Groove

Zewail‐Foote, M., & Hurley, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990241l · Cited by 215 · see citing works

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation

Jin, S. V., Gorfajn, B., Faircloth, G. T., & Scotto, K. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6775 · Cited by 206 · see citing works

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743

Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G. T., D’Incalci, M., & Mantovani, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6780 · Cited by 195 · see citing works

Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743

Martinez, E. J., Owa, T., Schreiber, S. L., & Corey, E. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3496 · Cited by 170 · see citing works

The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately equal to 40 degrees toward the major groove.

Rice, J. A., Crothers, D. M., Pinto, A. L., & Lippard, S. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.12.4158 · Cited by 168 · see citing works

In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

Izbicka, E., Lawrence, R., Raymond, É., Eckhardt, G., Faircloth, G. T., Jimeno, J. M., Clark, G. M., & VonHoff, D. D. (1998) · Annals of Oncology · doi:10.1023/a:1008224322396 · Cited by 137 · see citing works

Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.

Valoti, G., Nicoletti, M. I., Pellegrino, A., Jimeno, J. M., Hendriks, H. R., D’Incalci, M., Faircloth, G. T., & Giavazzi, R. (1998) · PubMed · Cited by 127 · see citing works

Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts.

Krishan, A., & Frei, E. (1976) · PubMed · Cited by 101 · see citing works

DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin

Broggini, M., Coley, H. M., Mongelli, N., Pesenti, E. A., Wyatt, M. D., Hartley, J. A., & D’Incalci, M. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.1.81 · Cited by 90 · see citing works

Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743 (ET-743)

Jimeno, J. M., Faircloth, G. T., Cameron, L., Meely, K., Vega, E., Gómez, A., Sousa-Faro, J. M. F., & RINEHART, K. L. J. (1996) · Drugs of the Future · doi:10.1358/dof.1996.021.11.385487 · Cited by 87 · see citing works

Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove

Takebayashi, Y., Pourquier, P., Yoshida, A., Kohlhagen, G., & Pommier, Y. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7196 · Cited by 86 · see citing works

Recent Progress with the DNA Repair Mutants of Chinese Hamster Ovary Cells

Thompson, L. H., Salazar, E. P., Brookman, K. W., Collins, C. C., Stewart, S. A., Busch, D. B., & Weber, C. A. (1987) · Journal of Cell Science · doi:10.1242/jcs.1984.supplement_6.6 · Cited by 83 · see citing works

NMR-Based Model of an Ecteinascidin 743−DNA Adduct

Moore, B. M., II, Seaman, F. C., & Hurley, L. H. (1997) · Journal of the American Chemical Society · doi:10.1021/ja9704500 · Cited by 81 · see citing works

Mitochondrial membrane potential measurement in rat cerebellar neurons by flow cytometry

Sureda, F. X., Escubedo, E., Gabriel, C., Comas, J., Camarasa, J., & Camins, A. (1997) · Cytometry · doi:10.1002/(sici)1097-0320(19970501)28:1 · Cited by 77 · see citing works

Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry.

Bonsing, B. A., Corver, W. E., Gorsira, M. C. B., van Vliet, M., Oud, P. S., Cj, C., & Fleuren, G. J. (1997) · PubMed · Cited by 73 · see citing works

Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata.

Guan, Y., Sakai, R., Rinehart, K. L., & Wang, A. H. ‐. (1993) · PubMed · Cited by 71 · see citing works

MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lung

Giaccone, G., van Ark-Otte, J., Rubio, G. J., Gazdar, A. F., Broxterman, H. J., Dingemans, A. C., Flens, M. J., Scheper, R. J., & Pinedo, H. M. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960611)66:6 · Cited by 66 · see citing works

Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15

Garcı́a-Rocha, M., García-Gravalos, M., & Ávila, J. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.176 · Cited by 52 · see citing works

Determination of the structural features of (+)-CC-1065 that are responsible for bending and winding of DNA

Lee, C. S., Sun, D., Kizu, R., & Hurley, L. H. (1991) · Chemical Research in Toxicology · doi:10.1021/tx00020a013 · Cited by 45 · see citing works

In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)

Ghielmini, M. E. G., Colli, E., Erba, E., Bergamaschi, D., Pampallona, S., Jimeno, J. M., Faircloth, G. T., & Sessa, C. (1998) · Annals of Oncology · doi:10.1023/a:1008430827281 · Cited by 45 · see citing works

Comparison of cell‐cycle phase perturbations induced by the DNA‐minor‐groove alkylator tallimustine and by melphalan in the SW626 cell line

Erba, E., Mascellani, E., Pifferi, A., & D’Incalci, M. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620211 · Cited by 24 · see citing works

Untitled work

(1998) · doi:10.1002/(sici)1097-0320(19980101)31:1

DNA and its associated processes as targets for cancer therapy

Hurley, L. H. (2002) · Nature reviews. Cancer · doi:10.1038/nrc749 · Cited by 1,350 · see citing works

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 863 · see citing works

The odyssey of marine pharmaceuticals: a current pipeline perspective

Mayer, A. M. S., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W. R., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C. M., & Shuster, D. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.005 · Cited by 669 · see citing works

Natural products in anticancer therapy

Ab, D. R. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00063-7 · Cited by 606 · see citing works

Marine Natural Products: A Source of Novel Anticancer Drugs

Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555 · see citing works

Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

Cesne, A. L., Blay, J., Judson, I. R., van Oosterom, A., Verweij, J., Radford, J. A., Lorigan, P. C., Rodenhuis, S., Ray-Coquard, I., Bonvalot, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.180 · Cited by 458 · see citing works

A Review of Trabectedin (ET-743): A Unique Mechanism of Action

D’Incalci, M., & Galmarini, C. M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0263 · Cited by 446 · see citing works

DNA minor groove binders as potential antitumor and antimicrobial agents

Baraldi, P. G., Bovero, A., Fruttarolo, F., Preti, D., Tabrizi, M. A., Pavani, M. G., & Romagnoli, R. (2004) · Medicinal Research Reviews · doi:10.1002/med.20000 · Cited by 377 · see citing works

Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production

Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F., Olimpio, C. O., Bonardi, C., Garbi, A., Lissoni, A. A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4037 · Cited by 286 · see citing works

Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells

Germano, G., Frapolli, R., Simone, M., Tavecchio, M., Erba, E., Pesce, S., Pasqualini, F., Grosso, F., Sanfilippo, R. G., Casali, P. G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2335 · Cited by 266 · see citing works

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

D’Incalci, M., Badri, N., Galmarini, C. M., & Allavena, P. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.149 · Cited by 219 · see citing works

Untitled work

(2011) · International Journal of Phytomedicine · Cited by 203 · see citing works

Are In Vitro Tests Suitable for Regulatory Use?

Hartung, T., & Daston, G. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp149 · Cited by 202 · see citing works

Mild Hypoxia Enhances Proliferation and Multipotency of Human Neural Stem Cells

Santilli, G., Lamorte, G., Carlessi, L., Ferrari, D., Nodari, L. R., Binda, E., Delia, D., Vescovi, A. L., & Filippis, L. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008575 · Cited by 192 · see citing works

Marine pharmacology in 2001–2: antitumour and cytotoxic compounds

Mayer, A. M. S., & Gustafson, K. R. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.09.005 · Cited by 177 · see citing works

Unique features of trabectedin mechanism of action

Larsen, A. K., Galmarini, C. M., & D’Incalci, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2918-1 · Cited by 173 · see citing works

Cross-Talk between Nucleotide Excision and Homologous Recombination DNA Repair Pathways in the Mechanism of Action of Antitumor Trabectedin

Herrero, A. B., Martı́n-Castellanos, C., Marco, E., Gago, F., & Moreno, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0179 · Cited by 172 · see citing works

Marine Natural Products in Clinical Use

Haque, N., Parveen, S., Tang, T., Wei, J., & Huang, Z. (2022) · Marine Drugs · doi:10.3390/md20080528 · Cited by 166 · see citing works

Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails

Sessa, C., de Braud, F., Perotti, A., Bauer, J. A., Curigliano, G., Noberasco, C., Zanaboni, F., Gianni, L., Marsoni, S., Jimeno, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.032 · Cited by 162 · see citing works

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

Damia, G. L. M., Silvestri, S., Carrassa, L., Filiberti, L., Faircloth, G. T., Liberi, G., Foiani, M., & D’Incalci, M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1221 · Cited by 160 · see citing works

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti‐tumour activity

Leal, J., Martínez, M., García-Hernández, V., Moneo, V., Domingo, A., Bueren‐Calabuig, J. A., Negri, A., Gago, F., Guillen-Navarro, M. J., Avilés, P., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00945.x · Cited by 157 · see citing works

Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743

Soares, D. G., Escargueil, A. E., Poindessous, V., Sarasin, A. R., de Gramont, A., Bonatto, D., Henriques, J. A. P., & Larsen, A. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609877104 · Cited by 156 · see citing works

Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives

Mabuchi, S., Sugiyama, T., & Kimura, T. (2016) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2016.27.e31 · Cited by 152 · see citing works

Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes

Barreca, M., Spanò, V., Montalbano, A., Cueto, M., Díaz‐Marrero, A. R., Deniz, İ., Erdoğan, A., Bilela, L. L., Moulin, C., de Givenchy, E. T., et al. (2020) · Marine Drugs · doi:10.3390/md18120619 · Cited by 150 · see citing works

Progress in the development and acquisition of anticancer agents from marine sources

Amador, M. L., Jimeno, J. M., Paz-Ares, L. G., Cortés-Funes, H., & Hidalgo, M. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg443 · Cited by 150 · see citing works

Gold from the sea: Marine compounds as inhibitors of the hallmarks of cancer

Schumacher, M., Kelkel, M., Dicato, M., & Diederich, M. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.02.002 · Cited by 138 · see citing works

Mode of action of trabectedin in myxoid liposarcomas

Giandomenico, S. D., Frapolli, R., Bello, E., Uboldi, S., Licandro, S. A., Marchini, S., Beltrame, L., Brich, S., Mauro, V., Tamborini, E., et al. (2013) · Oncogene · doi:10.1038/onc.2013.462 · Cited by 130 · see citing works

Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action

Aune, G. J., Furuta, T., & Pommier, Y. G. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200207000-00001 · Cited by 128 · see citing works

Antimicrobial Peptides from Marine Proteobacteria

Desriac, F., Jégou, C., Balnois, E., Brillet, B., Chevalier, P. L., & Fleury, Y. (2013) · Marine Drugs · doi:10.3390/md11103632 · Cited by 119 · see citing works

Antibiotics from Gram-negative bacteria: a comprehensive overview and selected biosynthetic highlights

Masschelein, J., Jenner, M., & Challis, G. L. (2017) · Natural Product Reports · doi:10.1039/c7np00010c · Cited by 118 · see citing works

Insights about clinically approved and Preclinically investigated marine natural products

Ghareeb, M. A., Tammam, M. A., El‐Demerdash, A., & Atanasov, A. G. (2020) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2020.09.001 · Cited by 115 · see citing works

Nanomedicine Strategies to Target Tumor-Associated Macrophages

Binnemars‐Postma, K., Storm, G., & Prakash, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050979 · Cited by 110 · see citing works

Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues

Tardy, C., Facompré, M., Laine, W., Baldeyrou, B., Garcı́a-Grávalos, D., Francesch, A., Mateo, C., Pastor, A., Jiménez, J. A., Manzanares, I., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.01.020 · Cited by 105 · see citing works

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

for the ET-743-INT-11 study group, Krasner, C. N., McMeekin, D. S., Chan, S. Y. T., Braly, P. S., Renshaw, F. G., Kaye, S. B., Provencher, D. M., Campos, S. M., & Gore, M. E. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604088 · Cited by 103 · see citing works

Chemistry and Biology of Acylfulvenes: Sesquiterpene-Derived Antitumor Agents

Tanasova, M., & Sturla, S. J. (2012) · Chemical Reviews · doi:10.1021/cr2001367 · Cited by 101 · see citing works

Role of homologous recombination in trabectedin-induced DNA damage

Tavecchio, M., Simone, M., Erba, E., Chiolo, I., Liberi, G., Foiani, M., D’Incalci, M., & Damia, G. L. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.01.003 · Cited by 98 · see citing works

Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets

Pereira, R. B., Evdokimov, N. M., Lefranc, F., Valentão, P., Kornienko, A., Pereira, D. M., Andrade, P. B., & Gomes, N. G. M. (2019) · Marine Drugs · doi:10.3390/md17060329 · Cited by 97 · see citing works

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

Laverdière, C., Kolb, E. A., Supko, J. G., Gorlick, R. G., Meyers, P. A., Maki, R. G., Wexler, L. H., Demetri, G. D., Healey, J. H., Huvos, A. G., et al. (2003) · Cancer · doi:10.1002/cncr.11563 · Cited by 97 · see citing works

Chapter 1 Molecular Modes of Action of Cytotoxic Alkaloids: From DNA Intercalation, Spindle Poisoning, Topoisomerase Inhibition to Apoptosis and Multiple Drug Resistance

Wink, M. (2007) · The Alkaloids. Chemistry and biology/The alkaloids. Chemistry and biology · doi:10.1016/s1099-4831(07)64001-2 · Cited by 96 · see citing works

Cinnamaldehyde and cuminaldehyde thiosemicarbazones and their copper(II) and nickel(II) complexes: A study to understand their biological activity

Bisceglie, F., Pinelli, S., Alinovi, R., Goldoni, M., Mutti, A., Camerini, A., Piola, L., Tarasconi, P., & Pelosi, G. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.07.014 · Cited by 95 · see citing works

Marine-derived anticancer agents in clinical trials

Schwartsmann, G., da Rocha, A. B., Mattei, J., & Lopes, R. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.8.1367 · Cited by 91 · see citing works

The combination of yondelis and cisplatin is synergistic against human tumor xenografts

D’Incalci, M., Colombo, T., Ubezio, P., Nicoletti, I., Giavazzi, R., Erba, E., Ferrarese, L., Meco, D., Riccardi, R., Sessa, C., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00490-8 · Cited by 90 · see citing works

Ecteinascidin-743 inhibits activated but not constitutive transcription.

Friedman, D., Hu, Z., Kolb, E. A., Gorfajn, B., & Scotto, K. W. (2002) · PubMed · Cited by 89 · see citing works

Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin

van Kesteren, C., de Vooght, M. M. M., Lázaro, L. L., Mathôt, R. A. A., Schellens, J. H. M., Jimeno, J. M., & Beijnen, J. H. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200308000-00001 · Cited by 88 · see citing works

Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650

Martinez, E. J., Corey, E. J., & Owa, T. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00082-5 · Cited by 88 · see citing works

Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

Twelves, C. J., Hoekman, K., Bowman, A., Vermorken, J. B., Anthoney, A., Smyth, J., van Kesteren, C., Beijnen, J. H., Uiters, J., Wanders, J., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00458-1 · Cited by 84 · see citing works

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

Villalona-Calero, M. A., Eckhardt, S. G., Weiss, G. R., Hidalgo, M. M., Beijnen, J. H., van Kesteren, C., Rosing, H., Campbell, E., Kraynak, M. A., Lázaro, L. L., et al. (2002) · PubMed · Cited by 82 · see citing works

Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells

Soares, D. G., Machado, M. S., Rocca, C. J., Poindessous, V., Ouaret, D., Sarasin, A. R., Galmarini, C. M., Henriques, J. A. P., Escargueil, A. E., & Larsen, A. K. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0252 · Cited by 81 · see citing works

DNA and Non-DNA Targets in the Mechanism of Action of the Antitumor Drug Trabectedin

David‐Cordonnier, M., Gajate, C., Olmea, O., Laine, W., de la Iglesia-Vicente, J., Perez, C., Cuevas, C., Otero, G., Manzanares, I., Bailly, C., et al. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.08.009 · Cited by 80 · see citing works

Challenges and Rewards of Research in Marine Natural Products Chemistry in Brazil

Berlinck, R. G. S., Hajdu, E., da Rocha, R. M., Luiz, J. H. H., Hernández, I. L. C., Seleghim, M. H. R., Granato, A. C., de Almeida, É. V. R., Núñez, C. V., Muricy, G. R. D. S., et al. (2004) · Journal of Natural Products · doi:10.1021/np0304316 · Cited by 79 · see citing works

Differential Cytostatic and Apoptotic Effects of Ecteinascidin-743 in Cancer Cells

Gajate, C., An, F., & Mollinedo, F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204644200 · Cited by 78 · see citing works

Apoptosis inducing lead compounds isolated from marine organisms of potential relevance in cancer treatment

Beesoo, R., Neergheen, V. S., Bhagooli, R., & Bahorun, T. (2014) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2014.03.005 · Cited by 78 · see citing works

Marine drugs for cancer: surfacing biotechnological innovations from the oceans

Jimenez, P. C., Wilke, D. V., & Costa-Lotufo, L. V. (2018) · Clinics · doi:10.6061/clinics/2018/e482s · Cited by 76 · see citing works

Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers

Stevens, E. V., Nishizuka, S., Antony, S., Reimers, M., Varma, S., Young, L., Munson, P. J., Weinstein, J. N., Kohn, E. C., & Pommier, Y. G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0192 · Cited by 76 · see citing works

Transcription-coupled DNA Double-Strand Breaks Are Mediated via the Nucleotide Excision Repair and the Mre11-Rad50-Nbs1 Complex

Guirouilh‐Barbat, J., Redon, C. E., & Pommier, Y. G. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-02-0215 · Cited by 75 · see citing works

Preclinical and clinical results with the natural marine product ET-743

D’Incalci, M., & Jimeno, J. M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.11.1843 · Cited by 72 · see citing works

Molecular pharmacology and antitumor activity of Zalypsis® in several human cancer cell lines

Martínez-Leal, J. F., García-Hernández, V., Moneo, V., Domingo, A., Bueren‐Calabuig, J. A., Negri, A., Gago, F., Guillen-Navarro, M. J., Avilés, P., Cuevas, C., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.003 · Cited by 71 · see citing works

Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.

Kanzaki, A., Takebayashi, Y., Ren, X. Q., Miyashita, H., Mori, S., Akiyama, S. I., & Pommier, Y. G. (2002) · PubMed · Cited by 69 · see citing works

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma

Italiano, A., Laurand, A., Laroche, A., Casali, P. G., Sanfilippo, R. G., Cesne, A. L., Judson, I. R., Blay, J., Ray-Coquard, I. L., Bui, B., et al. (2011) · Cancer · doi:10.1002/cncr.25925 · Cited by 67 · see citing works

A Phase I and Pharmacokinetic Study of Ecteinascidin-743 (Yondelis) in Children with Refractory Solid Tumors. A Children's Oncology Group Study

Lau, L. M. S., Supko, J., Blaney, S. M., Hershon, L., Seibel, N. L., Krailo, M., Qu, W., Malkin, D. M., Jimeno, J. M., Bernstein, M. L., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.672.11.2 · Cited by 66 · see citing works

ET-743: a novel agent with activity in soft-tissue sarcomas

Fayette, J., Ray-Coquard, I. L., Alberti, L., Boyle, H. J., Méeus, P., Decouvelaere, A., Thiesse, P., Sunyach, M., Ranchère‐Vince, D., & Blay, J. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000228740.70379.3f · Cited by 66 · see citing works

Trabectedin has promising antineoplastic activity in high‐grade meningioma

Preusser, M., Spiegl‐Kreinecker, S., Lötsch, D., Wöehrer, A., Schmook, M. T., Dieckmann, K. U., Saringer, W. F., Marosi, C., & Berger, W. (2012) · Cancer · doi:10.1002/cncr.27460 · Cited by 64 · see citing works

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.

Donald, S., Verschoyle, R. D., Greaves, P., Gant, T. W., Colombo, T., Zaffaroni, M., Frapolli, R., Zucchetti, M., D’Incalci, M., Meco, D., et al. (2003) · PubMed · Cited by 64 · see citing works

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)

Romano, M., Frapolli, R., Zangarini, M., Bello, E., Porcu, L., Galmarini, C. M., García‐Fernández, L., Cuevas, C., Allavena, P., Erba, E., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28213 · Cited by 63 · see citing works

Anticancer and antimetastatic activities of Renieramycin M, a marine tetrahydroisoquinoline alkaloid, in human non-small cell lung cancer cells.

Halim, H., Chunhacha, P., Suwanborirux, K., & Pithi Chanvorachote, B. (2011) · PubMed · Cited by 63 · see citing works

Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine

Erba, E., Bassano, L., Liberti, G., Muradore, I., Chiorino, G., Ubezio, P., Vignati, S., Codegoni, A. M., Desiderio, M. A., Faircloth, G. T., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600265 · Cited by 61 · see citing works

Disruption of nucleocytoplasmic trafficking of cyclin D1 and topoisomerase II by sanguinarine

Holy, J. M., Lamont, G., & Perkins, E. L. (2006) · BMC Cell Biology · doi:10.1186/1471-2121-7-13 · Cited by 60 · see citing works

Reactive oxygen species generation and mitochondrial dysfunction for the initiation of apoptotic cell death in human hepatocellular carcinoma HepG2 cells by a cyclic dipeptide Cyclo(-Pro-Tyr)

Karanam, G., & Arumugam, M. K. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05407-5 · Cited by 59 · see citing works

Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.

Takahashi, N., Li, W., Banerjee, D., Guan, Y., Wada-Takahashi, Y., Brennan, M. F., Chou, T., Scotto, K. W., & Bertino, J. R. (2002) · PubMed · Cited by 59 · see citing works

The Experience of Women Affected by Polycystic Ovary Syndrome: A Qualitative Study From Iran

Amiri, F. N., Tehrani, F. R., Simbar, M., Montazeri, A., & Mohammadpour, R. A. (2014) · Intern J Endocrinol Metab · doi:10.5812/ijem.13612 · Cited by 59 · see citing works

Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma

Schöffski, P., Dumez, H., Wolter, P., Stefan, C., Woźniak, A., Jimeno, J. M., & van Oosterom, A. T. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1609 · Cited by 58 · see citing works

A Human Immunodeficiency Virus Type 1 pol Gene-Derived Sequence (cPPT/CTS) Increases the Efficiency of Transduction of Human Nondividing Monocytes and T Lymphocytes by Lentiviral Vectors

Manganini, M., Serafini, M., Bambacioni, F., Casati, C., Erba, E., Follenzi, A., Naldini, L., Bernasconi, S., Gaipa, G., Rambaldi, A., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760372909 · Cited by 56 · see citing works

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial

Lorusso, D., Scambia, G., Pignata, S., Sorio, R., Amadio, G., Lepori, S., Mosconi, A. M., Pisano, C., Mangili, G., Maltese, G., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv608 · Cited by 55 · see citing works

Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer

Zhu, X., & Lang, J. (2017) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2017.28.e64 · Cited by 55 · see citing works

Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia

Banerjee, P., Zhang, R., Ivan, C., Galletti, G., Clise-Dwyer, K., Barbaglio, F., Scarfò, L., Aracil, M., Klein, C., Wierda, W. G., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0152 · Cited by 54 · see citing works

New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort

Hoffman, A., Lazar, A. J., Pollock, R. E., & Lev, D. C. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.11.001 · Cited by 52 · see citing works

How do dietary diatoms cause the sex reversal of the shrimp Hippolyte inermis Leach (Crustacea, Decapoda)

Zupo, V., & Messina, P. (2006) · Marine Biology · doi:10.1007/s00227-006-0524-9 · Cited by 53 · see citing works

Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients

Martı́nez, N., Sánchez‐Beato, M., Carnero, A., Moneo, V., Tercero, J. C., Fernández, I., Navarrete, M., Jimeno, J. M., & Piris, M. A. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0316 · Cited by 52 · see citing works

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

von Mehren, M., Schilder, R. J., Cheng, J. D., Temmer, E., Cardoso, T. M., Renshaw, F. G., Bayever, E., Zannikos, P., Yuan, Z., & Cohen, R. B. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn363 · Cited by 50 · see citing works

Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.

Scotlandi, K., Perdichizzi, S., Manara, M. C., Serra, M., Benini, S., Cerisano, V., Strammiello, R., Mercuri, M., Reverter‐Branchat, G., Faircloth, G. T., et al. (2002) · PubMed · Cited by 49 · see citing works

Synthetic studies on Ecteinascidin-743: synthesis of building blocks through Sharpless asymmetric dihydroxylation and aza-Michael reactions

Chandrasekhar, S., Reddy, N. R., & Rao, Y. S. (2006) · Tetrahedron · doi:10.1016/j.tet.2006.09.056 · Cited by 48 · see citing works

Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743,??Yondelis??) in Cancer Patients

Ruixo, J. J. P., Zannikos, P., Hirankarn, S., Stuyckens, K., Ludwig, E. A., Soto-Matos, A., Lázaro, L. L., & Owen, J. S. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746100-00005 · Cited by 46 · see citing works

Unique Features of the Mode of Action of ET-743

D’Incalci, M., Erba, E., Damia, G. L. M., Galliera, E., Carrassa, L., Marchini, S., Mantovani, R., Tognon, G., Fruscio, R., Jimeno, J. M., et al. (2002) · The Oncologist · doi:10.1634/theoncologist.7-3-210 · Cited by 46 · see citing works

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin

Colmegna, B., Uboldi, S., Frapolli, R., Licandro, S. A., Panini, N., Galmarini, C. M., Badri, N., Spanswick, V. J., Bingham, J. P., Kiakos, K., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.407 · Cited by 45 · see citing works

Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin

Casado, J. A., Rı́o, P., Marco, E., García-Hernández, V., Domingo, A., Pérez, L. M., Tercero, J. C., Vaquero, J. J., Albella, B., Gago, F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2432 · Cited by 45 · see citing works

Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.

Poindessous, V., Koeppel, F., Raymond, É., Comisso, M., Waters, S. J., & Larsen, A. K. (2003) · PubMed · Cited by 45 · see citing works

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

van Kesteren, C., Twelves, C. J., Bowman, A., Hoekman, K., Lázaro, L. L., Jimeno, J. M., Guzmán, C., Mathôt, R. A. A., Simpson, A., Vermorken, J. B., et al. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200204000-00007 · Cited by 45 · see citing works

A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer

Monk, B. J., Herzog, T. J., Wang, G., Triantos, S., Maul, R. S., Knoblauch, R. E., McGowan, T., Shalaby, W. S. W., & Coleman, R. L. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.12.043 · Cited by 44 · see citing works

Molecular evidence of inefficient transduction of proliferating human B lymphocytes by VSV-pseudotyped HIV-1-derived lentivectors

Serafini, M., Naldini, L., & Introna, M. (2004) · Virology · doi:10.1016/j.virol.2004.04.038 · Cited by 44 · see citing works

Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells

Açıkgöz, E., Güven, Ü., Düzağaç, F., Uslu, R., Kara, M., Soner, B. C., & Öktem, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141090 · Cited by 43 · see citing works

Trabectedin as a chemotherapy option for patients with BRCA deficiency

Monk, B. J., Lorusso, D., Italiano, A., Kaye, S. B., Aracil, M., Tanovı́c, A., & D’Incalci, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.009 · Cited by 42 · see citing works

Trabectedin therapy for sarcomas

Casali, P. G., Sanfilippo, R. G., & D’Incalci, M. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833aaac1 · Cited by 41 · see citing works

In vitro interaction between Ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects

Simoens, C., Korst, A. E. C., Pooter, C. M. J. D., Lambrechts, H. A. J., Pattyn, G. G. O., Faircloth, G. T., Lardon, F., & Vermorken, J. B. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601431 · Cited by 41 · see citing works

Development of distamycin-related DNA binding anticancer drugs

Marchini, S., Broggini, M., Sessa, C., & D’Incalci, M. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.9.1703 · Cited by 41 · see citing works

Selective Effects of the Anticancer Drug Yondelis (ET-743) on Cell-Cycle Promoters

Minuzzo, M., Ceribelli, M., Pitarque, M., Borrelli, S., Erba, E., diSilvio, A., D’Incalci, M., & Mantovani, R. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013615 · Cited by 41 · see citing works

Mechanism-based Pharmacokinetic/Pharmacodynamic Meta-analysis of Trabectedin (ET-743, Yondelis) Induced Neutropenia

Hing, J. P., Ruixo, J. J. P., Stuyckens, K., Soto-Matos, A., Lázaro, L. L., & Zannikos, P. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100259 · Cited by 41 · see citing works

ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas

Fayette, J., Ray-Coquard, I. L., Alberti, L., Ranchère‐Vince, D., Boyle, H. J., & Blay, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-10-827 · Cited by 40 · see citing works

Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular abberations

Verweij, J., & Baker, L. H. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.01.016 · Cited by 40 · see citing works

Extreme sensitivity to Yondelis® (Trabectedin, ET‐743) in low passaged sarcoma cell lines correlates with mutated p53

Moneo, V., Serelde, B. G., Fominaya, J. M., Martínez-Leal, J. F., Blanco‐Aparicio, C., Romero, L., Sánchez‐Beato, M., Cigudosa, J. C., Tercero, J. C., Piris, M. A., et al. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21073 · Cited by 40 · see citing works

Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo

Sulaiman, G. M., Ad'hiah, A. H., Al-Samarrae, K. W., Bagnati, R., Frapolli, R., Bello, E., Uboldi, S., Romano, M., Panini, N., Scanziani, E., et al. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.01.022 · Cited by 39 · see citing works

447 POSTER ARRY-520, a KSP inhibitor with potent in vitro and in vivo efficacy and pharmacodynamic activity in models of multiple myeloma

Woessner, R. D., Tunquist, B. J., Chlipala, E. A., Humphries, M., Trawick, D., Cox, A., Lee, P. M., Winkler, J., & Walker, D. H. (2008) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(08)72381-4 · Cited by 1 · see citing works

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

Damia, G. L. M., Silvestri, S., Carrassa, L., Filiberti, L., Faircloth, G. T., Liberi, G., Foiani, M., & D’Incalci, M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1221 · Cited by 160 · see citing works

Unique Features of the Mode of Action of ET-743

D’Incalci, M., Erba, E., Damia, G. L. M., Galliera, E., Carrassa, L., Marchini, S., Mantovani, R., Tognon, G., Fruscio, R., Jimeno, J. M., et al. (2002) · The Oncologist · doi:10.1634/theoncologist.7-3-210 · Cited by 46 · see citing works

ET-743: more than an innovative mechanism of action.

Scotto, K. W. (2002) · PubMed · Cited by 29 · see citing works

Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action

Aune, G. J., Furuta, T., & Pommier, Y. G. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200207000-00001 · Cited by 128 · see citing works